BACKGROUND: PCSK9 plays a key role in plasma cholesterol metabolism by modulating the expression of LDL receptors. OBJECTIVE AND METHODS: In this study we investigated the effects of two common polymorphism of the PCSK9 gene (E670G and I474V) on the intima media thickness of the common carotid artery and the possible relation with polymorphisms of apolipoprotein E in 1541 middle aged subjects selected from the general population enrolled in the PLIC study and confirmed the major findings in a second free-living population enrolled in the Ventimiglia study. RESULTS: 670G carriers showed significantly increased plasma total cholesterol, LDL-cholesterol, and Apo levels B while no significant differences were observed between carriers of the I474V SNP. IMT was significantly increased in 670G carriers compared to individuals homozygous for the E allele (0.640+/-0.102mm vs. 0.652+/-0.092mm, P<0.05). The presence of the 670G allele was also significantly associated with a greater progression of IMT compared to 670EE subjects. Plasma total cholesterol, LDL-cholesterol, apolipoprotein B, and IMT significantly increased from ApoE2;PCSK9-670EE carriers to ApoE4-PCSK9-670G carriers, while no significant differences were observed when the presence of the ApoE alleles was combined with that of the PCSK9 I474V SNP. In silico analysis on wild type and 670G variant showed several structural differences on the interactions of the loops of the "V" domain. CONCLUSIONS: The E670G polymorphism of the PCSK9 gene is associated with increased IMT progression in the general population. When the presence of 670G allele is stratified according to the ApoE gene alleles, ApoE2;PCSK9-670EE carriers show a more favorable plasma lipid profile and decreased IMT compared to ApoE4-PCSK9-670G carriers. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND:PCSK9 plays a key role in plasma cholesterol metabolism by modulating the expression of LDL receptors. OBJECTIVE AND METHODS: In this study we investigated the effects of two common polymorphism of the PCSK9 gene (E670G and I474V) on the intima media thickness of the common carotid artery and the possible relation with polymorphisms of apolipoprotein E in 1541 middle aged subjects selected from the general population enrolled in the PLIC study and confirmed the major findings in a second free-living population enrolled in the Ventimiglia study. RESULTS: 670G carriers showed significantly increased plasma total cholesterol, LDL-cholesterol, and Apo levels B while no significant differences were observed between carriers of the I474V SNP. IMT was significantly increased in 670G carriers compared to individuals homozygous for the E allele (0.640+/-0.102mm vs. 0.652+/-0.092mm, P<0.05). The presence of the 670G allele was also significantly associated with a greater progression of IMT compared to 670EE subjects. Plasma total cholesterol, LDL-cholesterol, apolipoprotein B, and IMT significantly increased from ApoE2;PCSK9-670EE carriers to ApoE4-PCSK9-670G carriers, while no significant differences were observed when the presence of the ApoE alleles was combined with that of the PCSK9I474V SNP. In silico analysis on wild type and 670G variant showed several structural differences on the interactions of the loops of the "V" domain. CONCLUSIONS: The E670G polymorphism of the PCSK9 gene is associated with increased IMT progression in the general population. When the presence of 670G allele is stratified according to the ApoE gene alleles, ApoE2;PCSK9-670EE carriers show a more favorable plasma lipid profile and decreased IMT compared to ApoE4-PCSK9-670G carriers. Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Bas J M Peters; Helmi Pett; Olaf H Klungel; Bruno H Ch Stricker; Bruce M Psaty; Nicole L Glazer; Kerri L Wiggins; Josh C Bis; Anthonius de Boer; Anke-Hilse Maitland-van der Zee Journal: Atherosclerosis Date: 2011-06-17 Impact factor: 5.162
Authors: Christoph J Griessenauer; Sean Farrell; Atom Sarkar; Ramin Zand; Vida Abedi; Neil Holland; Andrew Michael; Christopher L Cummings; Raghu Metpally; David J Carey; Oded Goren; Neil Martin; Philipp Hendrix; Clemens M Schirmer Journal: J Cereb Blood Flow Metab Date: 2018-09-05 Impact factor: 6.200